Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection
| Autor: | Günay Can, Ridvan Karaali, Mert Ahmet Kuşkucu, Harika Oyku Dinc, Sevgi Ergin, Bilge Caglar, Nese Saltoglu, Yesim Tuyji Tok, Bilgul Mete, Bekir Kocazeybek, Kenan Midilli, Beyhan Budak, Ilker Inanc Balkan, Dogukan Ozbey, Yagmur Ersoy |
|---|---|
| Přispěvatelé: | DİNÇ, HARİKA ÖYKÜ |
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty COVID-19 Vaccines Health Personnel Antibodies Viral Article Immune system Plaque reduction neutralization test Internal medicine medicine Humans Healthcare workers Chemiluminescent microparticle immunoassay General Veterinary General Immunology and Microbiology medicine.diagnostic_test biology SARS-CoV-2 business.industry Public Health Environmental and Occupational Health Antibody titer COVID-19 Middle Aged Vaccination Titer Infectious Diseases Immunoassay Antibody Formation Humoral immunity biology.protein Molecular Medicine Female CoronaVac Antibody business the anti-spike/RBD antibody |
| Zdroj: | Vaccine |
| Popis: | Background and Objectives Healthcare workers (HCWs) were among the first groups to be vaccinated in Turkey. The data to be obtained by the vaccination of HCWs would guide wide spread vaccination programs. Materials and Methods The study included 330 HCWs working at Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty Hospital and vaccinated with inactive CoronaVac (Sinovac Life Sciences, China) SARS-CoV-2 vaccine in two doses (28 days apart). Anti-Spike /RBD IgG levels were measured 14 days after the first dose and 28 days after the second dose. Chemiluminescent microparticle immunoassay (CMIA) (ARCHITECT IgG II Quant test, Abbott, USA), which is 100% compatible with plaque reduction neutralization test (PRNT), was used. Results Of the participants, 211 (63.9%) were female, 119 (36.1%) were male, and mean age was 39.6 ± 7.7 years. In those without prior COVID-19 history; (n = 255) antibody positivity was detected as 48.2% (95% CI: 42.1–54.3) 14 days after the first dose of vaccine, and 99.2% (95% CI: 98.1–100) at day 28 after the second dose. Antibody titers were significantly lower in patients with hypertension (p = 0.011). In those with prior history of COVID-19 (n = 75); both the antibody positivity rates after the first vaccine (48.2% vs 100%, p = 0.000) and the anti-spike/RBD antibody levels after the second vaccine (with a ≥ 1050 AU/mL titer equivalent to PRNT 1/80 dilution) was significant than infection-naive group (25.9% vs. 54.7%, p = 0.000). Antibody positivity after two doses of vaccination for all study group was 99.4% (95% CI: 98.6–100). Conclusions Two doses CoronaVac produce effective humoral immunity in HCWs. Antibody response is significantly higher in those with prior history of COVID-19 than infection-naive group. Given no significant benefit of the second dose, a single shot of vaccination may be sufficient for those with prior history of COVID-19. Monitoring humoral and cellular immune responses, considering new variants, is required to validate this approach. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|